商絡電子(300975.SZ):尚未代理海力士品牌
格隆匯7月18日丨有投資者向商絡電子(300975.SZ)提問,“近年來全球人工智能產業革命大爆發,引爆對AIGPU巨大需求,同時引發大量HBM(高帶寬DRAM)存儲芯片的爆發性需求。公司已取得了TDK(東電化)、Samsung(三星電機)、Yageo(國巨)、TE(泰科)、兆易創新、長鑫存儲等90餘家國內外知名原廠代理資質。公司客户有寧德時代,比亞迪、蔚來,大疆,等。公司是否與海力士談判存儲芯片的代理資質合同?公司應加大長鑫存儲,三星的存儲芯片銷售”
商絡電子回覆稱,公司尚未代理海力士品牌,並將認真考慮您提出的建議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.